CAH — Cardinal Health, Inc.

The immediate mood is cautious-constructive rather than euphoric. Q4 FY26 non-GAAP EPS of $2.91 beat consensus, but the company missed revenue, guided FY27 FCF down to $3.5-4.0B from $4.97B, and the CEO sold roughly $29M of stock near $236. Wall Street still rates CAH a Buy with a $273.22 consensus price target, but the post-earnings fade from $258.30 to $235.13 reflects real skepticism about cash generation and growth durability.

After a weak FY25 (revenue fell from roughly $226.7B in FY24 to $222.6B in FY25 and quarterly YoY growth was negative through FY25), CAH inflected sharply in FY26: quarterly YoY revenue growth was +22.4%, +18.4%, +11.0%, and +6.1% across the four FY26 quarters. That is a clear acceleration into FY26, but with decelerating momentum as the year progressed; Q4's 6.1% growth also missed the $65.03B consensus. More positive is the margin story: gross margin expanded from roughly 3.2-3.3% in FY24 to about 3.85% in FY26, and operating margin improved from roughly 0.7% to about 1.0%, though still razor-thin. Non-GAAP FY26 EPS grew 37% to $11.26, and FY27 guidance of $12.40-$12.60 implies another 13-15% gain. Q4 is a noisy quarter—GAAP EPS was $1.69 vs. non-GAAP $2.91, with a $0.31 one-time tariff refund—so the quality of the beat is real but not as clean as the headline.

As of 2026-08-27, CAH is fairly valued, not cheap. The stock trades at 32.3x trailing GAAP EPS, but that multiple is distorted by one-off and non-cash items; on FY27 consensus non-GAAP EPS of $12.544, the forward P/E is about 18.7x. The 5-year average P/E of 40.4x is not a useful anchor because GAAP earnings were depressed, and the 5-year average P/S of 0.14x understates the current margin improvement. The trailing PEG of 2.6x looks rich, but the forward PEG is closer to 1.4x against 13-15% EPS growth. Given the negative equity, current ratio of 0.88, and guided-down FCF, the market is paying a reasonable but not discounted price for a legitimate specialty-pharma growth story.

The stock has already re-rated and is pricing in continued FY27 EPS growth and specialty-pharma momentum. At $235.13, you are paying roughly 18.7x forward non-GAAP EPS for 13-15% EPS growth, while guided FY27 FCF of $3.5-4.0B implies only a mid-single-digit FCF yield against the $55.1B market cap. If CAH hits the midpoint of FY27 EPS guidance and FCF lands near the top of the range, the stock can work toward the $273 consensus target. If revenue stays in single digits and FCF comes in near $3.5B, the multiple is more likely to compress toward 17-18x forward earnings, putting fair value closer to $220-240.

As of 2026-08-27, RSI-14 stood at 52.81, which is neutral—not overbought or oversold. Price was 0.1% above the 20-day SMA, 1.1% above the 50-day SMA, and 9.5% above the 200-day SMA. That is a consolidating but intact uptrend below the $258.30 all-time high. The entry-timing implication is that there is no technical urgency to chase; a pullback toward the 50-day SMA (around $232-233) or the 200-day SMA (around $215) would offer a better risk/reward, while a sustained close above $258.30 would signal a new leg higher.

• Medicare Drug Price Negotiation under the IRA is resetting manufacturer-distributor economics and could pressure distribution fees and contract structures.
• Tariff and IEEPA policy swings created a one-time refund that flattered Q4 FY26 and leave FY27 gross margin and FCF exposed to import-cost volatility.
• Specialty pharmaceuticals, biosimilars, and GLP-1-class volume growth are shifting mix toward higher-margin distribution and 3PL services.
• Interest rates and working capital costs matter more than usual because CAH runs a current ratio of 0.88 with a large payable/receivable base.
• Long-running opioid settlement liabilities are a decades-long cash outlay that limits balance-sheet flexibility.

• Q1 FY27 earnings, expected in late October/early November 2026: the market will focus on whether revenue growth re-accelerates and whether FCF tracks the $3.5-4.0B guide.
• Buyback execution under the expanded $6.4B authorization—aggressive repurchases would mechanically lift FY28 EPS and signal management confidence.
• New cell-and-gene therapy distribution wins and integration of the July 2026 At-Home Solutions tuck-in acquisitions.
• Any favorable regulatory clarification on IRA distributor fees or tariff refunds that improves the FY27 margin outlook.

• FY27 adjusted FCF guidance of $3.5-4.0B is a meaningful step down from $4.97B; weaker cash generation could compress the multiple.
• Revenue growth is decelerating—from +22.4% YoY in Q1 FY26 to +6.1% in Q4—and Q4 missed consensus revenue.
• Negative stockholders' equity of -$2.88B, $6.86B of long-term debt, and a 0.88 current ratio leave little balance-sheet cushion.
• Opioid/legal liabilities and IRA-driven pricing pressure remain structural overhangs on distributor margins.
• The CEO's $29M insider sale at roughly $236, cutting his direct stake by over 50%, is a caution flag worth monitoring.

CAH has a genuine specialty-pharma growth engine, improving margins, solid ROIC near 13%, and FY27 EPS guidance that still implies 13-15% growth. But at $235.13, that growth is mostly priced in, FCF is being guided down, and the balance sheet is stretched from years of buybacks. This is a good business at a fair price—not a compelling buy and not a short—so the honest lean is neutral: hold for existing investors, wait for a better entry on weakness for new money.

Calculated by applying a 20.0x forward P/E to FY2027 consensus non-GAAP EPS of $12.544—a modest premium to the current 18.7x forward multiple, justified by 13-15% EPS growth and ~13% ROIC, but tempered by negative equity and the weaker FCF outlook. This yields $250.88, a fair-value midpoint between the current price and the analyst target.